Aktienanalyse zu Bionano Genomics, Inc. (BNGO)BNGOBionano Genomics, Inc.

Bionano Genomics, Inc. is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company offers optical genome mapping (OGM) solutions for applications across basic, translational and clinical research. It also offers a platform-agnostic software solution, which integrates sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants, and absence of heterozygosity across the genome in one consolidated view. The Company additionally offers nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. The Company markets and sells OGM systems, including the Saphyr system, which delivers OGM data to enable ultra-sensitive and ultra-specific detection of all classes of structural variation (SV). It operates in the Healthcare sector (LABORATORY ANALYTICAL INSTRUMENTS industry).

Bionano Genomics Inc (BNGO) is currently trading at $1.135, which is near its 52-week low of $1.00. The stock has a low RSI of 42.064, indicating it is not yet oversold, and the forward P/E ratio is 0, suggesting uncertainty in future earnings. While the gross margin has improved to 52.80% in Q2 2026, the company continues to report significant net losses, with a net income of -$7,423,000 for the same quarter. The upcoming earnings report on November 10, 2026, could provide further insights into its financial health, but currently, the stock shows mixed signals with a recent 5-day change of -1.30%.

2 analysts cover BNGO: 2 rate it Buy, 0 Hold and 0 Sell. The average price target is 7.50.